Dr. Susan M. O'Brien discusses about added value of second generation BTKi and elaborates NCCN guidelines for CLL/SLL
Dr. Susan M. O'Brien, US
Dr. Susan M. O'Brien, Associate Director Clinical Science, Chao Family Comprehensive Cancer centre, United states, discusses about added value of second generation BTKi and emphasise on the following points
• Kinase selectivity of BTK inhibitor.
• RESONATE 2 trial, ELEVATE TN trial, SEQUOIA trial and compares the 2-year PFS data.
• NCCN guidelines treatment regime for CLL/SLL.
• FLAIR trial and a publication on major adverse cardiovascular events and hypertension in ibrutinib treated patients
• CLL 14 trial and the progression free survival.
• Comparison of ibrutinib with 2nd generation BTKi through ELEVATE RR trial and describes the adverse events for bleeding, diarrhoea, arthralgia.
• Advantages of second generation BTKi over Ibrutinib in high-risk relapse patients.
Explore more videos
CLL Case Presentation
Dr. Khalil Al Farsi, Oman
2nd GCC Haematology Forum- CLL Case Discussion Focus on Safety Profile of BTKi
Dr. Ruba Taha, Qatar
Panel discussion
Dr. Ayman Al Hejazi, KSA